Recap: Sierra Oncology Q1 Earnings
Sierra Oncology (NASDAQ:SRRA) reported its Q1 earnings results on Friday, May 6, 2022 at 07:00 AM.
Here's what investors need to know about the announcement.
The Week Ahead In Biotech (April 17-April 23): J&J, Abbott Earnings, Adcom Test For TG Therapeutics And More
Biotech stocks retreated in the week ending April 14, lock-stepping with the broader market. The news flow was light during the holiday-shortened week and ahead of the imminent first-quarter reporting season.
Jefferies Downgrades Sierra Oncology to Hold, Raises Price Target to $55
Jefferies analyst Maury Raycroft downgrades Sierra Oncology (NASDAQ:SRRA) from Buy to Hold and raises the price target from $39 to $55.
Oppenheimer Downgrades Sierra Oncology to Perform, Raises Price Target to $55
Oppenheimer analyst Jay Olson downgrades Sierra Oncology (NASDAQ:SRRA) from Outperform to Perform and raises the price target from $45 to $55.
Sierra Oncology Stock Is Soaring: Here’s Why
Sierra Oncology Inc (NASDAQ: SRRA) shares are trading significantly higher Wednesday after the company announced it will be acquired by GlaxoSmithKline PLC (NYSE: GSK) for $55 per share in cash, representing an a
HC Wainwright & Co. Downgrades Sierra Oncology to Neutral, Raises Price Target to $55
HC Wainwright & Co. analyst Joseph Pantginis downgrades Sierra Oncology (NASDAQ:SRRA) from Buy to Neutral and raises the price target from $51 to $55.
GlaxoSmithKline Scoops Up Rare Cancer-Focused Sierra Oncology In $1.9B Cash Deal
GlaxoSmithKline plc (NYSE:GSK) has agreed to acquire Sierra Oncology Inc (NASDAQ:SRRA) for $55 per share in cash, representing an approximate total…
